Status:
COMPLETED
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Dyslipidemia
Hypertension
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of p...
Eligibility Criteria
Inclusion
- Subjects with diagnosed hypertension receiving treatment with Norvasc 5 or 10 mg and who also have 3 additional cardiovascular risk factors, including dyslipidemia.
Exclusion
- Subjects who are taking the following prohibited medications within 14 days of screening: lipid-lowering therapy, calcium channel blocker other then Norvasc, \>3 antihypertensive agents (including Norvasc)
- Subjects that have not been on a stable dose of Norvasc for at least 4 weeks
- Subjects with a history of coronary heart disease, stroke, or Pulmonary Vascular Disease (PVD)
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT00412113
Start Date
January 1 2007
End Date
April 1 2008
Last Update
February 11 2021
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35216
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35234
4
Pfizer Investigational Site
Mesa, Arizona, United States, 85206